Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
Animals
Antibodies, Monoclonal
/ chemistry
Antineoplastic Agents, Immunological
/ chemistry
Biomarkers, Tumor
Clinical Decision-Making
Combined Modality Therapy
Disease Management
Disease Susceptibility
Hematologic Neoplasms
/ diagnosis
Humans
Immunoconjugates
/ chemistry
Molecular Targeted Therapy
/ adverse effects
Neoplasms
/ drug therapy
Prognosis
Treatment Outcome
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
09
04
2021
revised:
24
05
2021
accepted:
16
06
2021
pubmed:
20
6
2021
medline:
4
1
2022
entrez:
19
6
2021
Statut:
ppublish
Résumé
Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we summarize the different therapeutic mAbs that have been successfully developed against various tumor-expressed antigens and examine our current understanding of their different mechanisms of antitumor action. These mechanisms of action (MOA) largely center on the stimulation of different innate immune effector processes, which appear to be principally responsible for the efficacy of most unconjugated mAb therapies against cancer. This is evident in studies of mAbs targeting antigens for hematologic cancers, with emerging data also demonstrating the critical nature of innate immune-mediated mechanisms in the efficacy of anti-HER2 mAbs against solid HER2
Identifiants
pubmed: 34145037
pii: 0008-5472.CAN-21-1109
doi: 10.1158/0008-5472.CAN-21-1109
pmc: PMC8448950
mid: NIHMS1718779
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4641-4651Subventions
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238217
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009111
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Br J Cancer. 2011 Jul 26;105(3):366-71
pubmed: 21750556
JAMA Oncol. 2021 Apr 01;7(4):573-584
pubmed: 33480963
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
J Eur Acad Dermatol Venereol. 2010 Jun;24(6):692-6
pubmed: 19925598
Oncogene. 2016 Nov 24;35(47):6053-6064
pubmed: 27157621
Br J Cancer. 2006 Jan 30;94(2):259-67
pubmed: 16404427
Antibodies (Basel). 2020 Jul 20;9(3):
pubmed: 32698317
MAbs. 2018 Aug/Sep;10(6):864-875
pubmed: 30081724
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
Clin Cancer Res. 2016 Dec 1;22(23):5747-5754
pubmed: 27189162
Ann Oncol. 2013 Oct;24(10):2492-2500
pubmed: 23827380
Cancer Res. 2006 Feb 1;66(3):1630-9
pubmed: 16452222
Genomics. 2001 Mar 1;72(2):119-27
pubmed: 11401424
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
BMC Cancer. 2014 Apr 28;14:295
pubmed: 24773917
Clin Lung Cancer. 2018 Mar;19(2):130-138.e2
pubmed: 29158123
J Clin Invest. 1988 Apr;81(4):1122-8
pubmed: 2450893
J Clin Oncol. 2014 Jul 1;32(19):2074-7
pubmed: 24868026
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Eur J Cancer. 2018 Mar;92:11-19
pubmed: 29413685
Clin Breast Cancer. 2007 Jun;7(8):600-7
pubmed: 17592672
Semin Nucl Med. 1989 Oct;19(4):282-94
pubmed: 2678480
Clin Cancer Res. 2016 Jul 1;22(13):3249-59
pubmed: 26842237
JAMA Oncol. 2015 Nov;1(8):1154-61
pubmed: 26204261
Antibodies (Basel). 2020 Oct 28;9(4):
pubmed: 33126570
Immunity. 2008 Mar;28(3):425-35
pubmed: 18328742
Br J Haematol. 2018 Mar;180(6):808-820
pubmed: 29468712
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Eur J Cancer. 1999 Jan;35(1):117-24
pubmed: 10211099
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Curr Opin Immunol. 2008 Aug;20(4):444-9
pubmed: 18585457
MAbs. 2018 Jan;10(1):143-158
pubmed: 29200314
Front Oncol. 2019 Sep 20;9:849
pubmed: 31616627
Mol Pathol. 2002 Jun;55(3):193-9
pubmed: 12032231
Mol Immunol. 2020 Mar;119:48-58
pubmed: 31978707
Lancet Oncol. 2015 Feb;16(2):208-20
pubmed: 25596660
Cancer Treat Rev. 2018 Jul;68:111-123
pubmed: 29944978
Haematologica. 2020 Jun;105(6):1494-1506
pubmed: 32482755
Expert Rev Anticancer Ther. 2006 Mar;6(3):445-61
pubmed: 16503861
Clin Cancer Res. 2007 Sep 1;13(17):5133-43
pubmed: 17785568
Cancer Immunol Immunother. 2009 Nov;58(11):1853-64
pubmed: 19319529
Oncotarget. 2018 Jun 22;9(48):28989-29006
pubmed: 29989029
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
Trends Biotechnol. 2019 Jan;37(1):9-16
pubmed: 29945725
Immunotherapy. 2016 Sep;8(9):1097-117
pubmed: 27485082
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Oncol Lett. 2017 Sep;14(3):2961-2969
pubmed: 28928834
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Cancer Res. 2002 Jul 15;62(14):4132-41
pubmed: 12124352
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
N Engl J Med. 2007 Nov 15;357(20):2040-8
pubmed: 18003960
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
Histopathology. 2002 Apr;40(4):339-47
pubmed: 11943018
Nat Cancer. 2021 Jan;2(1):18-33
pubmed: 35121890
Cancer Res. 2006 Apr 15;66(8):3992-5
pubmed: 16618717
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Mol Immunol. 2008 Dec;46(2):242-9
pubmed: 18838169
Breast Cancer Res. 2011;13(6):R121
pubmed: 22123186
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
Onco Targets Ther. 2016 Oct 05;9:6037-6048
pubmed: 27785050
Nat Rev Immunol. 2014 Feb;14(2):94-108
pubmed: 24445665
J Immunol. 2011 Mar 15;186(6):3401-9
pubmed: 21321106
Expert Rev Clin Pharmacol. 2016;9(5):647-53
pubmed: 26934530
J Transl Med. 2013 Dec 12;11:307
pubmed: 24330813
Breast Cancer Res Treat. 2010 Jul;122(1):35-43
pubmed: 19701706
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
J Clin Oncol. 2015 May 10;33(14):1574-83
pubmed: 25779558
Clin Cancer Res. 2021 Feb 15;27(4):922-927
pubmed: 32962979
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Nat Commun. 2020 Sep 14;11(1):4591
pubmed: 32929084
Mol Cell Biol. 2009 Jun;29(12):3319-31
pubmed: 19364815
Am J Cancer Res. 2012;2(6):676-90
pubmed: 23226614
Mol Oncol. 2013 Jun;7(3):580-94
pubmed: 23474221
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
Cancer Sci. 2011 Oct;102(10):1761-8
pubmed: 21718386
Breast Cancer Res Treat. 2011 Jan;125(1):65-72
pubmed: 20229175
J Natl Cancer Inst. 2016 Dec 16;108(12):
pubmed: 27986884
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Cell Cycle. 2005 Jan;4(1):87-95
pubmed: 15611642
Nat Commun. 2020 Nov 17;11(1):5824
pubmed: 33203854
Nat Rev Urol. 2021 Feb;18(2):93-103
pubmed: 33239713
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Mol Cancer. 2010 Jun 07;9:139
pubmed: 20529262
Adv Ther. 2017 May;34(5):1015-1035
pubmed: 28361465
Clin Colorectal Cancer. 2018 Jun;17(2):85-96
pubmed: 29576427
Cancer Res. 2009 Dec 15;69(24):9330-6
pubmed: 19934333
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Cancer Res. 2011 Mar 1;71(5):1515-9
pubmed: 21343397
Target Oncol. 2009 Apr;4(2):107-19
pubmed: 19452131
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689243
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
pubmed: 21482773
J Surg Oncol. 1997 Mar;64(3):222-30
pubmed: 9121154
Cancer Treat Rev. 2015 Sep;41(8):680-9
pubmed: 26045227
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Blood Cancer J. 2020 Apr 28;10(3):30
pubmed: 32341336
Haematologica. 2009 Mar;94(3):423-7
pubmed: 19211644
Nat Rev Clin Oncol. 2014 Jan;11(1):8-9
pubmed: 24322598
Trends Immunol. 2016 Feb;37(2):141-153
pubmed: 26778079
Front Immunol. 2019 Jun 07;10:1296
pubmed: 31231397
PLoS Pathog. 2013 Jan;9(1):e1003115
pubmed: 23326231
J Clin Invest. 2012 Mar;122(3):1066-75
pubmed: 22326955
Mol Cancer Ther. 2001 Dec;1(2):85-94
pubmed: 12467226
Ann Pharmacother. 2013 Feb;47(2):210-8
pubmed: 23386066
Nat Rev Cancer. 2012 Mar 22;12(4):278-87
pubmed: 22437872
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Lancet Oncol. 2019 Jul;20(7):998-1010
pubmed: 31101489
Cancer Treat Rev. 2017 Feb;53:38-46
pubmed: 28056413
Expert Opin Biol Ther. 2017 Jul;17(7):887-893
pubmed: 28434255
Clin Cancer Res. 2016 Nov 1;22(21):5229-5237
pubmed: 27217441
Blood. 2012 Apr 12;119(15):3523-33
pubmed: 22354003
Blood. 2003 Jan 15;101(2):391-8
pubmed: 12393555
Blood. 1989 May 15;73(7):1936-41
pubmed: 2653466
Protein Cell. 2018 Jan;9(1):63-73
pubmed: 28986820
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
BMJ. 2020 Sep 21;370:m3176
pubmed: 32958461
Br J Cancer. 2010 Jan 5;102(1):134-43
pubmed: 19920829
Breast Cancer Res. 2012 Aug 08;14(4):R116
pubmed: 22873525
Clin Cancer Res. 2013 Mar 15;19(6):1476-86
pubmed: 23363817
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Cancer Immunol Res. 2015 Feb;3(2):173-83
pubmed: 25387893
Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34
pubmed: 16616284
Future Oncol. 2021 Jan;17(2):127-135
pubmed: 32954807
Cancer Med. 2016 Dec;5(12):3454-3463
pubmed: 27882700
Drugs. 2020 Apr;80(5):501-508
pubmed: 32144719
J Clin Oncol. 2012 May 10;30(14):1594-600
pubmed: 22393084
Breast Cancer Res. 2011;13(6):R123
pubmed: 22129105
Mol Pharmacol. 2014 Nov;86(5):485-91
pubmed: 24944188
Cancer Res. 2013 Nov 1;73(21):6471-83
pubmed: 24046294
J Clin Invest. 2008 May;118(5):1700-11
pubmed: 18398507
MAbs. 2016 Oct;8(7):1361-1370
pubmed: 27380003